Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5247-5252

  Saito, Hiroshi ^a   Takada, Yoshiki ^b   Ichinose, Yukito ^b   Eguchi, Kenji ^b   Kudoh, Shinzoh ^b   Matsui, Kaoru ^b   Nakagawa, Kazuhiko ^b   Takada, Minoru ^b   Negoro, Shunichi ^b   Tamura, Kenji ^b   Ando, Masahiko ^b   Tada, Takuhito ^b   Fukuoka, Masahiro ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPNEA; ELECTROLYTE DISTURBANCE; ESOPHAGITIS; FEBRILE NEUTROPENIA; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; LIVER DISEASE; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FEVER; HOSPITALIZATION; JAPAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SMALL CELL CARCINOMA; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DIARRHEA; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FEVER; HUMANS; INFECTION; JAPAN; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947608646     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.1605     Document Type: Article

References (24)

1. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
2. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992
3. Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
4. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002
5. Bonner JA, Sloan JA, Shanahan TG, et al: Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 17:2681-2691, 1999
6. Schild S, Brindle JS, Geyer SM, et al: Long term results of a phase III trial comparing once a day radiotherapy (QD RT) or twice a day radiotherapy (BID RT) in limited stage small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 22:631, 2003 (abstr 2536)
7. Jeremic B, Shibamoto Y, Acimovic L, et al: Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J Clin Oncol 15:893-900, 1997
8. Negoro S, Fukuoka M, Niitani H, et al: A phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 10:241, 1991 (abstr 822)
9. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
10. Saito H, Takada Y, Eguchi K, et al: Randomized phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplain or irinotecan, cisplatin and etoposide in patients with limited stage small-cell lung cancer (SCLC): A West Japan Thoracic Oncology Group trial. Proc Am Soc Clin Oncol 21:311a, 2002 (abstr 1240)
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
12. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Kubota K, Nishiwaki Y, Sugiura T, et al: Pilot study of concurrent cisplatin and etoposide plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer. Japan Clinical Oncology Group 9903. Clin Cancer Res 11:5534-5538, 2005
15. Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043, 2006
16. Oka M, Fukuda M, Kuba M, et al: Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 38:1998-2004, 2002
17. Yokoyama A, Kurita Y, Saijo N, et al: Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer. Br J Cancer 78:257-262, 1998
18. Langer CJ, Swann S, Werner-Wasik M, et al: Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. J Clin Oncol 24:378s, 2006 (suppl; abstr 7058)
19. Han JY, Cho KH, Lee DH, et al: Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23:3488-3494, 2005
20. Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837-4845, 2004
21. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al: Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17:543-552, 2006
22. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24:1057-1063, 2006
23. Ettinger DS, Berkey BA, Abrams RA, et al: Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23:4991-4998, 2005
24. Takeda Y, Tsuduki E, Izumi S, et al: A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. Br J Cancer 93:1341-1349, 2005